Okyo registers Phase 3 trial of urcosimod for neuropathic corneal pain
Okyo Pharma Ltd listed a new Phase 3 study of urcosimod ophthalmic solution, called NEPTUNE, for neuropathic corneal pain, not yet recruiting.
Okyo Pharma Ltd had one registry update for the week of September 24, 2026.
- Okyo registered a Phase 3, randomized, placebo-controlled trial (NCT07838506, acronym NEPTUNE) testing Urcosimod, formerly called OK-101, ophthalmic solution in participants with Neuropathic Corneal Pain (NCP)1. The study is not yet recruiting, with an estimated start of September 2026 and estimated primary completion in May 20271, and plans to enroll 111 participants1, with the primary outcome being the change from baseline at Week 12 in ocular pain assessed by VAS score1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.